Early cancer detection remains one of the greatest challenges in modern medicine. While significant advances have been made in cancer treatment, patient survival often depends on diagnosing the disease before symptoms become apparent. This has fueled the search for reliable, non-invasive biomarkers that can identify cancer at its earliest stages.
Among the most promising resources for biomarker discovery are human urine samples. Easily accessible and completely non-invasive to collect, urine contains valuable molecular information that can support the development of next-generation diagnostic tests. Today, urine samples for research are increasingly used in oncology, liquid biopsy studies, and translational medicine to investigate novel biomarkers capable of improving early cancer detection.
📚 A recent study published in Analytical Chemistry (2024) highlights the remarkable potential of urinary exosomes and microRNA profiling for identifying cancer. We are proud that human urine samples supplied by BIOMEDICA CRO were among those used in this innovative research.
Early Cancer Detection Through Urinary Exosome microRNA Profiling 🧬
The study was conducted by a multidisciplinary research team led by scientists from the Institute of Science Tokyo and Nagoya University, with contributions from researchers at The University of Tokyo, Hokkaido University, Osaka University, Tokyo Medical University, Kansai University, QST, and biotechnology company Craif.
Their objective was to determine whether combinations of microRNAs isolated from urinary exosomes could distinguish individuals with cancer from healthy controls.
To achieve this, researchers developed a novel nanowire-based platform capable of efficiently capturing urinary exosomes before analyzing their microRNA content. Instead of relying on a single biomarker, the team evaluated multiple microRNA signatures using computational analysis, significantly improving the ability to differentiate cancer and non-cancer samples.
The publication discusses applications involving several cancer types, including lung cancer and brain tumors, demonstrating the broad potential of urinary exosome profiling for future cancer screening strategies.
Although further clinical validation is still required before routine clinical implementation, the findings provide another important step toward developing accurate, non-invasive diagnostic tools capable of detecting cancer at much earlier stages.
The full article is available by clicking here: Early Cancer Detection via Multi-microRNA Profiling of Urinary Exosomes Captured by Nanowires.
BIOMEDICA CRO Human Urine Biospecimens Contributed to Innovative Cancer Research 🎗️
We are pleased to continue highlighting scientific publications in which BIOMEDICA CRO biospecimens have contributed to advancing biomedical research.
According to the study methodology, commercially available human urine biospecimens were obtained from several international biospecimen providers, including our company. Following sample collection, urinary exosomes were isolated and analyzed to identify microRNA signatures associated with cancer.
We are proud that BIOMEDICA CRO was one of the suppliers supporting this research. Collaborations like this demonstrate how high-quality, ethically collected biospecimens contribute to the development of innovative diagnostic technologies and accelerate translational cancer research worldwide.
🌍 Supporting Global Biospecimen Needs in Biomedical Research: Urine Samples and more
High-quality biospecimens remain the foundation of successful biomedical research, from biomarker discovery and diagnostic development to drug development and translational medicine. At BIOMEDICA CRO, we are proud to support pharmaceutical companies, biotechnology organizations, diagnostic developers, CROs, and academic researchers by providing ethically sourced human biospecimens accompanied by comprehensive clinical data.
Our continuously expanding inventory includes more than 45,000 banked biospecimens, while our prospective collection capabilities enable customized patient recruitment and sample processing tailored to individual study protocols.
We offer a broad range of biospecimen types to support diverse research applications, including:
Blood-derived samples:
- 🔬 Whole blood
- 🔬 Plasma
- 🔬 Buffy coat
- 🔬 PBMCs
- 🔬 Serum
- 🔬 Platelet layer, and more
Tissue samples:
- 🔬 FFPE blocks
- 🔬 Fresh frozen tissue
- 🔬 Viable frozen tissue (cryopreserved tissue), and more
Other biospecimens:
- 🔬 Whole urine, urine supernatant and urine cell pellets
- 🔬 Synofial fluid
- 🔬 Saliva
- 🔬 Stool samples, and more
Our collection supports a wide variety of therapeutic areas, including oncology, neurology, cardiology, infectious diseases, gastroenterology, dermatology, endocrinology, hematology, gynecology, urology, respiratory diseases, autoimmune disorders, and many others. We also provide healthy donor samples and normal control cohorts for comparative studies.
Whether your project focuses on early cancer detection, liquid biopsy, biomarker discovery, diagnostic innovation, drug development, or translational research, BIOMEDICA CRO is committed to delivering high-quality human biospecimens and reliable scientific support to help advance your research.
🌐 Interested? Explore our inventory of 45,000+ banked biospecimens by clicking here. Use available filters 🔍 to identify the most suitable samples and share your list with us so we can discuss tailored options for your study.
📩 Contact us: office@biomedica-cro.com.
🚀 Stay connected on LinkedIn for updates on biospecimen availability, research collaborations, and industry insights 📊.
